A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial-Reference-Cited by-同舟云学术

A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial

Published:2015-12-02 Issue:4 Volume:172 Page:535-544
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Advani Ranjana H.¹,Ansell Stephen M.²,Lechowicz Mary J.³,Beaven Anne W.⁴,Loberiza Fausto⁵,Carson Kenneth R.⁶,Evens Andrew M.⁷,Foss Francine⁸,Horwitz Steven⁹,Pro Barbara¹⁰,Pinter-Brown Lauren C.¹¹,Smith Sonali M.¹²,Shustov Andrei R.¹³,Savage Kerry J.¹⁴,M. Vose Julie⁵

Affiliation:

1. Medical Oncology; Stanford Cancer Institute; Stanford CA USA

2. Division of Hematology; Mayo Clinic; Rochester MN USA

3. Winship Cancer Institute; Emory University School of Medicine; Atlanta GA USA

4. Medicine-Oncology; Duke University Medical Center; Durham NC USA

5. Division of Hematology/Oncology; University of Nebraska Medical Center; Omaha NE USA

6. Division of Medical Oncology; Washington University School of Medicine; St. Louis MO USA

7. Division of Hematology/Oncology; Tufts Medical Center; Boston MA USA

8. Yale University Cancer Center; New Haven CT USA

9. Hematology/Oncology; Memorial Sloan-Kettering Cancer Center; New York NY USA

10. Medical Oncology; Jefferson University Hospital; Philadelphia PA USA

11. Hematology/Oncology; UCLA Geffen School of Medicine; Los Angeles CA USA